Survival following allogeneic transplant in patients with myelofibrosis
Top Cited Papers
Open Access
- 12 May 2020
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (9), 1965-1973
- https://doi.org/10.1182/bloodadvances.2019001084
Abstract
Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for myelofibrosis (MF). In this large multicenter retrospective study, overall survival (OS) in MF patients treated with allogeneic HCT (551 patients) and without HCT (non-HCT) (1377 patients) was analyzed with Cox proportional hazards model. Survival analysis stratified by the Dynamic International Prognostic Scoring System (DIPSS) revealed that the first year of treatment arm assignment, due to upfront risk of transplant-related mortality (TRM), HCT was associated with inferior OS compared with non-HCT (non-HCT vs HCT: DIPSS intermediate 1 [Int-1]: hazard ratio [HR] = 0.26, P < .0001; DIPSS-Int-2 and higher: HR, 0.39, P < .0001). Similarly, in the DIPSS low-risk MF group, due to upfront TRM risk, OS was superior with non-HCT therapies compared with HCT in the first-year post treatment arm assignment (HR, 0.16, P = .006). However, after 1 year, OS was not significantly different (HR, 1.38, P = .451). Beyond 1 year of treatment arm assignment, an OS advantage with HCT therapy in Int-1 and higher DIPSS score patients was observed (non-HCT vs HCT: DIPSS-Int-1: HR, 2.64, P < .0001; DIPSS-Int-2 and higher: HR, 2.55, P < .0001). In conclusion, long-term OS advantage with HCT was observed for patients with Int-1 or higher risk MF, but at the cost of early TRM. The magnitude of OS benefit with HCT increased as DIPSS risk score increased and became apparent with longer follow-up.This publication has 51 references indexed in Scilit:
- Myelofibrosis Treatment Algorithm 2018Blood Cancer Journal, 2018
- Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMTBritish Journal of Haematology, 2018
- Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk Predicts Post-Transplant OutcomesTransplantation and Cellular Therapy, 2017
- A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosisLeukemia, 2017
- Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow TransplantationHaematologica, 2014
- Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM‐TC)British Journal of Haematology, 2010
- Hematopoietic Cell Transplantation as Curative Therapy for Idiopathic Myelofibrosis, Advanced Polycythemia Vera, and Essential ThrombocythemiaTransplantation and Cellular Therapy, 2007
- Pilot study of reduced‐intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosisBritish Journal of Haematology, 2005
- Stem cell transplantation for myelofibrosis: a report from two Canadian centersBone Marrow Transplantation, 2003
- Score test of homogeneity for survival dataLifetime Data Analysis, 1995